

## Clinical Policy: Risankizumab-rzaa (Skyrizi)

Reference Number: IL.PHAR.426

Effective Date: 1.1.20

Last Review Date: 4.17.25

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Risankizumab-rzaa (Skyrizi™) is an interleukin-23 (IL-23) blocker.

### FDA Approved Indication(s)

Skyrizi is indicated for the treatment of:

- Moderate-to-severe plaque psoriasis (PsO) in adults who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis (PsA) in adults
- Moderately to severely active Crohn's disease (CD) in adults

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation® that Skyrizi is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Plaque Psoriasis (must meet all):

1. Diagnosis of moderate-to-severe PsO as evidenced by involvement of one of the following (a or b):
  - a.  $\geq 3\%$  of total body surface area;
  - b. Hands, feet, scalp, face, or genital area;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age  $\geq 18$  years;
4. Member meets one of the following (a, b or c):
  - a. Failure of a  $\geq 3$  consecutive month trial of methotrexate (MTX) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
  - b. If intolerance or contraindication to MTX (*see Appendix D*), failure of a  $\geq 3$  consecutive month trial of cyclosporine at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
  - c. Member has intolerance or contraindication to MTX and cyclosporine, and failure of phototherapy, unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of at least TWO of the following, each used for  $\geq 3$  consecutive months, unless contraindicated or clinically significant adverse effects are experienced: Enbrel®, adalimumab-adbm, adalimumab-ryvk (Simlandi), Cimzia®;

- \*Prior authorization is required for Enbrel, adalimumab products, and Cimzia*
6. Failure of the following used for  $\geq 3$  consecutive months: Cosentyx<sup>®</sup>;  
*\*Prior authorization may be required for Cosentyx*
  7. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (see Section III: Diagnoses/Indications for which coverage is NOT authorized);
  8. Dose does not exceed 150 mg at weeks 0 and 4, then every 12 weeks thereafter.

**Approval duration: 6 months**

**B. Psoriatic Arthritis (must meet all):**

1. Diagnosis of PsA;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age  $\geq 18$  years;
4. Failure of ALL of the following, each used for  $\geq 3$  consecutive months, unless clinically significant adverse effects are experienced or all are contraindicated (a and b):
  - a. Enbrel<sup>®</sup>, Cimzia<sup>®</sup>, adalimumab-adbm and adalimumab-ryvk (Simlandi) unless the member has had a history of failure of two TNF blockers;
  - b. If member has not responded or is intolerant to one or more TNF blockers, Xeljanz<sup>®</sup>/Xeljanz XR<sup>®</sup>, unless member has cardiovascular risk and benefits do not outweigh the risk of treatment;
  - c. Cosentyx, unless clinically significant adverse effects are experienced or all are contraindicated.

*\*Prior authorization may be required for Adalimumab products, Cosentyx<sup>®</sup>, Enbrel, Xeljanz/Xeljanz XR;*

5. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (see Section III: Diagnoses/Indications for which coverage is NOT authorized);

6. Dose does not exceed 150 mg at weeks 0 and 4, then every 12 weeks thereafter.

**Approval duration: 6 months**

**C. Crohns Disease (must meet all):**

1. Diagnosis of CD;
2. Prescribed by or in consultation with a gastroenterologist;
3. Age  $\geq 18$  years;
4. Member meets one of the following (a or b):
  - a. Failure of a  $\geq 3$  consecutive month trial of at least ONE immunomodulator (e.g., azathioprine, 6-mercaptopurine [6-MP], MTX) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;
  - b. Medical justification supports inability to use immunomodulators (see Appendix E);
5. Failure of a  $\geq 3$  consecutive month trial of adalimumab-adbm or adalimumab-ryvk (Simlandi) AND Cimzia<sup>®</sup>, unless clinically significant adverse effects are experienced or all are contraindicated;  
*\*Prior authorization may be required for adalimumab and TNF blockers*
6. Member does not have combination use of biological disease-modifying antirheumatic drugs or JAK inhibitors (see Section III: Diagnoses/Indications for which coverage is NOT authorized);

7. Dose does not exceed all of the following (a, b, and c):
  - a. Induction: 600 mg at weeks 0, 4, and 8;
  - b. Maintenance: 360 mg at week 12 and every 8 weeks thereafter;
  - c. Quantity does not exceed one single dose vial or pre-filled cartridge per dose 600 mg at weeks 0, 4, and 8, followed by 360 mg at week 12 and every 8 weeks thereafter.

**Approval duration: 6 months**

**D. Ulcerative Colitis** (must meet all):

1. Diagnosis of UC;
2. Prescribed by or in consultation with a gastroenterologist;
3. Age  $\geq$  18 years;
4. Documentation of a Mayo Score  $\geq$  6 (*see Appendix F*);
5. Failure of an 8-week trial of systemic corticosteroids, unless contraindicated or clinically significant adverse effects are experienced;
6. Member meets the following used for  $\geq$  3 consecutive months, unless clinically significant adverse effects are experienced or are contraindicated (*see Appendix D*):
  - a. Failure of adalimumab-adbm and adalimumab-ryvk (Simlandi), unless the member has had history of failure of two TNF blockers;  
*\*Prior authorization may be required for Humira*
7. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
  1. Dose does not exceed both of the following (a and b):
    - a. Induction: 1,200 mg at weeks 0, 4, and 8;
    - b. Maintenance (both i and ii):
      - i. 360 mg at week 12 and every 8 weeks thereafter;
      - ii. Quantity does not exceed one pre-filled cartridge per dose.

**Approval duration: 6 months**

**E. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All indications in Section I (must meet all):**

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
4. If request is for a dose increase, new dose does not exceed one of the following (a or b):
  - a. For PsA or PsO: 150 mg every 12 weeks;
  - b. For CD: both (i and ii):
    - i. 360 mg every 8 weeks;
    - ii. 1 pre-filled cartridge every 8 weeks.

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 or evidence of coverage documents.
- B.** Combination use of biological disease-modifying antirheumatic drugs (bDMARDs), including any tumor necrosis factor (TNF) antagonists [Cimzia<sup>®</sup>, Enbrel<sup>®</sup>, Simponi<sup>®</sup>, Avsola<sup>™</sup>, Inflectra<sup>™</sup>, Remicade<sup>®</sup>, Renflexis<sup>™</sup>], interleukin agents [Arcalyst<sup>®</sup> (IL-1 blocker), Ilaris<sup>®</sup> (IL-1 blocker), Kineret<sup>®</sup> (IL-1RA), Actemra<sup>®</sup> (IL-6RA), Kevzara<sup>®</sup> (IL-6RA), Stelara<sup>®</sup> (IL-12/23 inhibitor), Cosentyx<sup>®</sup> (IL-17A inhibitor), Taltz<sup>®</sup> (IL-17A inhibitor), Siliq<sup>™</sup> (IL-17RA), Ilumya<sup>™</sup> (IL-23 inhibitor), Skyrizi<sup>™</sup> (IL-23 inhibitor), Tremfya<sup>®</sup> (IL-23 inhibitor)], janus kinase inhibitors (JAKi) [Xeljanz<sup>®</sup>/Xeljanz<sup>®</sup> XR, Rinvoq<sup>™</sup>], anti-CD20 monoclonal antibodies [Rituxan<sup>®</sup>, Riabni<sup>™</sup>, Ruxience<sup>™</sup>, Truxima<sup>®</sup>, and Rituxan Hycela<sup>®</sup>], selective co-stimulation modulators [Orencia<sup>®</sup>], or integrin receptor antagonists [Entyvio<sup>®</sup>] because of the possibility of increased immunosuppression, neutropenia and increased risk of infection.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CD: Crohn's Disease

FDA: Food and Drug Administration

IL-23: interleukin-23  
JAKi: Janus kinase inhibitors  
MTX: methotrexate

PsA: Psoriatic Arthritis  
PsO: plaque psoriasis

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
azathioprine (Azasan <sup>®</sup> , Imuran <sup>®</sup> )	<b>CD*</b> 1.5 – 2 mg/kg/day PO	3 mg/kg/day
cyclosporine (Sandimmune <sup>®</sup> , Neoral <sup>®</sup> )	<b>PsO</b> 2.5 – 4 mg/kg/day PO divided BID	4 mg/kg/day
6-mercaptopurine (Purixan <sup>®</sup> )	<b>CD*</b> 50 mg PO QD or 1 – 2 mg/kg/day PO	2 mg/kg/day
methotrexate (Rheumatrex <sup>®</sup> )	<b>CD*</b> 15 – 25 mg/week IM or SC <b>PsO</b> 10 – 25 mg/week PO or 2.5 mg PO Q12 hr for 3 doses/week	30 mg/week
Enbrel <sup>®</sup> (etanercept)	<b>PsA</b> 25 mg SC twice weekly or 50 mg SC once weekly	50 mg/week
Cimzia <sup>®</sup> (certolizumab)	<b>CD</b> <u>Initial dose:</u> 400 mg SC at 0, 2, and 4 weeks <u>Maintenance dose:</u> 400 mg SC every 4 weeks	400 mg every 4 weeks
Humira <sup>®</sup> (adalimumab)	<b>CD</b> <u>Initial dose:</u> 160 mg SC on Day 1, then 80 mg SC on Day 15 <u>Maintenance dose:</u> 40 mg SC every other week starting on Day 29	40 mg every other week
Xeljanz <sup>®</sup> (tofacitinib)	<b>PsA</b> 5 mg PO BID	10 mg/day
Xeljanz XR <sup>®</sup> (tofacitinib extended-release)	<b>PsA</b> 11 mg PO QD	11 mg/day

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients
- Boxed warning(s): none reported

*Appendix D: General Information*

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.
- In a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial, Skyrizi was shown to be not beneficial in treatment of severe asthma. The time to the first asthma worsening was shorter and the annualized rate of asthma worsening was higher with risankizumab than with placebo.

*Appendix E: CD and Immunomodulator Medical Justification*

- The following may be considered for medical justification supporting inability to use an immunomodulator for CD:
  - Inability to induce short-term symptomatic remission with a 3-month trial of systemic glucocorticoids
  - High-risk factors for intestinal complications may include:
    - Initial extensive ileal, ileocolonic, or proximal GI involvement
    - Initial extensive perianal/severe rectal disease
    - Fistulizing disease (e.g., perianal, enterocutaneous, and rectovaginal fistulas)
    - Deep ulcerations
    - Penetrating, stricturing or stenosis disease and/or phenotype
    - Intestinal obstruction or abscess
  - For TNF-inhibitors, high risk factors for postoperative recurrence may include:
    - Less than 10 years duration between time of diagnosis and surgery
    - Disease location in the ileum and colon
    - Perianal fistula
    - Prior history of surgical resection
    - Use of corticosteroids prior to surgery

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
PsA, PsO	150 mg SC at Week 0, Week 4 and every 12 weeks thereafter	150 mg every 12 weeks
CD	<u>Induction</u> : 600 mg IV at Week 0, Week 4 and Week 8	IV: 600 mg/dose

Indication	Dosing Regimen	Maximum Dose
	<u>Maintenance</u> : 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter	SC: 360 mg every 8 weeks

**VI. Product Availability**

- Subcutaneous injection:
  - o Single-dose prefilled syringes: 75 mg/0.83 mL, 150 mg/mL
  - o Single-dose prefilled pen: 150 mg/mL
  - o Single-dose prefilled cartridges: 180 mg/1.2 mL, 360 mg/2.4 mL
- Intravenous infusion:
  - o Single-dose vial: 600 mg/10 mL

**VII. References**

1. Skyrizi Prescribing Information. North Chicago, IL: Abbvie Inc. June 2024. Available at: [https://www.rxabbvie.com/pdf/skyrizi\\_pi.pdf](https://www.rxabbvie.com/pdf/skyrizi_pi.pdf). Accessed June 25, 2024.
2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72. doi:10.1016/j.aad.201811.057.
3. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–712. doi:10.1136/annrheumdis-2020-217159
4. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. American College of Rheumatology. 2019; 71(1):5-32. doi: 10.1002/art.40726.
5. Brightling CE, Nair P, Cousins DJ, Louis R, and Sign D. Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial. N Engl J Med 2021; 385:1669-1679. DOI: 10.1056/NEJMoa2030880.
6. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology 2021; 160:2496-2508. <https://doi.org/10.1053/j.gastro.2021.04.022>.
7. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020;158:1450–1461. <https://doi.org/10.1053/j.gastro.2020.01.006>.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Code	Description
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
New policy created, adapted CP.PHAR.426 Risankizumab-rzaa (Skyrizi) policy.	12.11.19	1.7.20
2Q 2021 Annual Review: <b>updated</b> Diagnosis Diagnosis of moderate-to-severe PsO as evidenced by involvement of one of the following (a or b): a. $\geq 3\%$ of total body surface area; b. Hands, feet, scalp, face, or genital area; <b>Updated</b> Diagnoses/Indications for which coverage is NOT authorized: Combination use of biological disease-modifying antirheumatic drugs (bDMARDs); <b>Updated</b> Product Availability; <b>added</b> new 150 mg/mL prefilled pen and syringe formulations Reviewed and updated References	6.22.21	
3Q2022 Annual Review: updated policy with Crohn’s disease indication, new vial and prefilled cartridge formulations, new contraindication, and addition of Appendix E; reference reviewed and updated.	8.16.22	
RT4: added new 180 mg/1.2 mL single-dose prefilled cartridge dosage form and quantity limit stating that only one single dose vial or pre-filled cartridge is allowed per dose for CD. Template changes applied to other diagnoses/indications and continued therapy section.	11.29.22	
Added HCPCS code: [J2327].	2.27.23	
2Q 2024 annual review: updated t/f agents with preferred options; references reviewed.	4.5.24	
RT4: added newly approved Ulcerative Colitis indication to criteria.	11.6.24	
2Q2025 Annual Review: updated preferred adalimumab products.	4.17.25	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage

decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.